AAPL296.17+1.87 (+0.64%) ▲|ABBV233.39-1.37 (-0.58%) ▼|ABT91.16+0.63 (+0.69%) ▲|ACN130.37+3.36 (+2.65%) ▲|ADBE198.66+1.23 (+0.62%) ▲|AMAT578.80-7.08 (-1.21%) ▼|AMD514.52-5.33 (-1.03%) ▼|AMGN351.58+4.57 (+1.32%) ▲|AMT175.26-4.13 (-2.30%) ▼|AMZN238.38+4.27 (+1.82%) ▲|AVGO381.94+1.79 (+0.47%) ▲|AXP342.97+5.19 (+1.54%) ▲|BA221.73+5.02 (+2.32%) ▲|BAC57.68-0.24 (-0.41%) ▼|BKNG184.47+15.53 (+9.19%) ▲|BLK991.23-24.11 (-2.37%) ▼|BMY55.08-0.46 (-0.82%) ▼|BNY144.82-2.47 (-1.68%) ▼|BRK-B495.66+2.85 (+0.58%) ▲|C143.98-0.99 (-0.68%) ▼|CAT984.43+0.19 (+0.02%) ▲|CL92.13+0.70 (+0.77%) ▲|CMCSA22.69-0.12 (-0.50%) ▼|COF201.69+3.88 (+1.96%) ▲|COP106.94-3.03 (-2.76%) ▼|COST962.36+4.68 (+0.49%) ▲|CRM153.87+0.45 (+0.29%) ▲|CSCO119.86-1.30 (-1.07%) ▼|CVS101.30-0.27 (-0.27%) ▼|CVX171.69-4.29 (-2.44%) ▼|DE607.48+15.54 (+2.63%) ▲|DHR189.23+10.26 (+5.73%) ▲|DIS102.37-1.16 (-1.12%) ▼|DUK125.54+0.49 (+0.39%) ▲|EMR141.96-1.19 (-0.83%) ▼|FDX312.40-4.85 (-1.53%) ▼|GD346.64-3.71 (-1.06%) ▼|GE366.85+10.38 (+2.91%) ▲|GEV1,057.39+22.41 (+2.17%) ▲|GILD125.60+0.55 (+0.44%) ▲|GM79.77+0.82 (+1.04%) ▲|GOOG345.86-0.22 (-0.06%) ▼|GOOGL346.38+0.29 (+0.08%) ▲|GS1,080.34-14.10 (-1.29%) ▼|HD340.96+16.51 (+5.09%) ▲|HON227.98+5.61 (+2.52%) ▲|IBM264.16-0.78 (-0.29%) ▼|INTC131.24-1.04 (-0.79%) ▼|INTU267.81+9.76 (+3.78%) ▲|ISRG403.88+0.70 (+0.17%) ▲|JNJ239.61+0.53 (+0.22%) ▲|JPM332.93-1.22 (-0.36%) ▼|KO80.91+0.60 (+0.75%) ▲|LIN518.29+6.03 (+1.18%) ▲|LLY1,109.84+2.76 (+0.25%) ▲|LMT497.34-6.34 (-1.26%) ▼|LOW220.94+7.40 (+3.47%) ▲|LRCX367.50-3.83 (-1.03%) ▼|MA495.59+7.52 (+1.54%) ▲|MCD274.87+3.21 (+1.18%) ▲|MDLZ61.99+0.93 (+1.52%) ▲|MDT80.62-0.01 (-0.01%) ▼|META560.45-1.75 (-0.31%) ▼|MMM166.27+4.43 (+2.74%) ▲|MO72.01+0.40 (+0.56%) ▲|MRK120.49+0.89 (+0.74%) ▲|MS221.30-4.73 (-2.09%) ▼|MSFT372.07-1.87 (-0.50%) ▼|MU1,029.53-22.24 (-2.11%) ▼|NEE87.10+0.67 (+0.78%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.84-0.55 (-1.29%) ▼|NOW94.38-1.57 (-1.63%) ▼|NVDA198.63-1.37 (-0.69%) ▼|ORCL158.00-7.17 (-4.34%) ▼|PEP142.44+0.39 (+0.27%) ▲|PFE24.02-0.71 (-2.85%) ▼|PG152.30+1.44 (+0.95%) ▲|PLTR114.32-2.38 (-2.04%) ▼|PM177.92-0.77 (-0.43%) ▼|QCOM196.60-7.53 (-3.69%) ▼|RTX186.37-0.02 (-0.01%) ▼|SBUX104.22+3.17 (+3.14%) ▲|SCHW91.81-1.36 (-1.46%) ▼|SO95.05+0.12 (+0.13%) ▲|SPG220.53+3.79 (+1.75%) ▲|T22.44-0.38 (-1.64%) ▼|TMO490.90+21.55 (+4.59%) ▲|TMUS182.91-1.66 (-0.90%) ▼|TSLA377.36-4.25 (-1.11%) ▼|TXN303.70-0.66 (-0.22%) ▼|UBER74.02+4.35 (+6.24%) ▲|UNH404.57-4.69 (-1.14%) ▼|UNP260.11+1.50 (+0.58%) ▲|UPS105.06-0.78 (-0.73%) ▼|USB60.14+0.09 (+0.14%) ▲|V332.83+4.35 (+1.32%) ▲|VZ45.68-1.06 (-2.26%) ▼|WFC84.22+0.09 (+0.11%) ▲|WMT119.43+0.01 (+0.01%) ▲|XOM136.36-3.38 (-2.42%) ▼|AAPL296.17+1.87 (+0.64%) ▲|ABBV233.39-1.37 (-0.58%) ▼|ABT91.16+0.63 (+0.69%) ▲|ACN130.37+3.36 (+2.65%) ▲|ADBE198.66+1.23 (+0.62%) ▲|AMAT578.80-7.08 (-1.21%) ▼|AMD514.52-5.33 (-1.03%) ▼|AMGN351.58+4.57 (+1.32%) ▲|AMT175.26-4.13 (-2.30%) ▼|AMZN238.38+4.27 (+1.82%) ▲|AVGO381.94+1.79 (+0.47%) ▲|AXP342.97+5.19 (+1.54%) ▲|BA221.73+5.02 (+2.32%) ▲|BAC57.68-0.24 (-0.41%) ▼|BKNG184.47+15.53 (+9.19%) ▲|BLK991.23-24.11 (-2.37%) ▼|BMY55.08-0.46 (-0.82%) ▼|BNY144.82-2.47 (-1.68%) ▼|BRK-B495.66+2.85 (+0.58%) ▲|C143.98-0.99 (-0.68%) ▼|CAT984.43+0.19 (+0.02%) ▲|CL92.13+0.70 (+0.77%) ▲|CMCSA22.69-0.12 (-0.50%) ▼|COF201.69+3.88 (+1.96%) ▲|COP106.94-3.03 (-2.76%) ▼|COST962.36+4.68 (+0.49%) ▲|CRM153.87+0.45 (+0.29%) ▲|CSCO119.86-1.30 (-1.07%) ▼|CVS101.30-0.27 (-0.27%) ▼|CVX171.69-4.29 (-2.44%) ▼|DE607.48+15.54 (+2.63%) ▲|DHR189.23+10.26 (+5.73%) ▲|DIS102.37-1.16 (-1.12%) ▼|DUK125.54+0.49 (+0.39%) ▲|EMR141.96-1.19 (-0.83%) ▼|FDX312.40-4.85 (-1.53%) ▼|GD346.64-3.71 (-1.06%) ▼|GE366.85+10.38 (+2.91%) ▲|GEV1,057.39+22.41 (+2.17%) ▲|GILD125.60+0.55 (+0.44%) ▲|GM79.77+0.82 (+1.04%) ▲|GOOG345.86-0.22 (-0.06%) ▼|GOOGL346.38+0.29 (+0.08%) ▲|GS1,080.34-14.10 (-1.29%) ▼|HD340.96+16.51 (+5.09%) ▲|HON227.98+5.61 (+2.52%) ▲|IBM264.16-0.78 (-0.29%) ▼|INTC131.24-1.04 (-0.79%) ▼|INTU267.81+9.76 (+3.78%) ▲|ISRG403.88+0.70 (+0.17%) ▲|JNJ239.61+0.53 (+0.22%) ▲|JPM332.93-1.22 (-0.36%) ▼|KO80.91+0.60 (+0.75%) ▲|LIN518.29+6.03 (+1.18%) ▲|LLY1,109.84+2.76 (+0.25%) ▲|LMT497.34-6.34 (-1.26%) ▼|LOW220.94+7.40 (+3.47%) ▲|LRCX367.50-3.83 (-1.03%) ▼|MA495.59+7.52 (+1.54%) ▲|MCD274.87+3.21 (+1.18%) ▲|MDLZ61.99+0.93 (+1.52%) ▲|MDT80.62-0.01 (-0.01%) ▼|META560.45-1.75 (-0.31%) ▼|MMM166.27+4.43 (+2.74%) ▲|MO72.01+0.40 (+0.56%) ▲|MRK120.49+0.89 (+0.74%) ▲|MS221.30-4.73 (-2.09%) ▼|MSFT372.07-1.87 (-0.50%) ▼|MU1,029.53-22.24 (-2.11%) ▼|NEE87.10+0.67 (+0.78%) ▲|NFLX72.74-0.09 (-0.12%) ▼|NKE41.84-0.55 (-1.29%) ▼|NOW94.38-1.57 (-1.63%) ▼|NVDA198.63-1.37 (-0.69%) ▼|ORCL158.00-7.17 (-4.34%) ▼|PEP142.44+0.39 (+0.27%) ▲|PFE24.02-0.71 (-2.85%) ▼|PG152.30+1.44 (+0.95%) ▲|PLTR114.32-2.38 (-2.04%) ▼|PM177.92-0.77 (-0.43%) ▼|QCOM196.60-7.53 (-3.69%) ▼|RTX186.37-0.02 (-0.01%) ▼|SBUX104.22+3.17 (+3.14%) ▲|SCHW91.81-1.36 (-1.46%) ▼|SO95.05+0.12 (+0.13%) ▲|SPG220.53+3.79 (+1.75%) ▲|T22.44-0.38 (-1.64%) ▼|TMO490.90+21.55 (+4.59%) ▲|TMUS182.91-1.66 (-0.90%) ▼|TSLA377.36-4.25 (-1.11%) ▼|TXN303.70-0.66 (-0.22%) ▼|UBER74.02+4.35 (+6.24%) ▲|UNH404.57-4.69 (-1.14%) ▼|UNP260.11+1.50 (+0.58%) ▲|UPS105.06-0.78 (-0.73%) ▼|USB60.14+0.09 (+0.14%) ▲|V332.83+4.35 (+1.32%) ▲|VZ45.68-1.06 (-2.26%) ▼|WFC84.22+0.09 (+0.11%) ▲|WMT119.43+0.01 (+0.01%) ▲|XOM136.36-3.38 (-2.42%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: therapies

newssourceFORcompanyinformationcontent1marketreleases

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

The Ensign Group Schedules Second Quarter Earnings Call for Friday, July 25, 2025

SAN JUAN CAPISTRANO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it expects to issue its second quarter 2025 financial results on Thursday, July 24, 2025.

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Update On Clinical Trial Milestone – CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, July 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers